Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.59 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.52 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.49 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170881 | 1.00 | CRBN (0.65) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL30170866 | 0.93 | CRBN (0.67) | CRBNCSNK1A1MAP1LC3B | |
| SCHEMBL21759475 | 0.93 | CRBN (0.67) | CRBNCSNK1A1MAP1LC3B | |
| SCHEMBL24637376 | 0.86 | CRBN (0.69) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL30569130 | 0.86 | CRBN (0.69) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL29614730 | 0.85 | CRBN (0.65) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL20234357 | 0.85 | CRBN (0.65) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL24046272 | 0.85 | CRBN (0.65) | CRBNCSNK1A1IKZF2 | |
| SCHEMBL31722330 | 0.85 | CRBN (0.60) | CRBNCSNK1A1IKZF2GSPT1CYP2C19 | |
| SCHEMBL21877059 | 0.84 | CRBN (0.64) | CRBNCSNK1A1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-08-20 | — | — | US | disclosed |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2024-04-30 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2020038415-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885 |
| US-11969472-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885CSNK1A1 23/4885IKZF2 2290/4885 |
| US-12065442-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, NTRK1, ERBB2 | CRBN 194/4885CSNK1A1 48/4885IKZF2 1536/4885 |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESR1, ESRRG | CRBN 324/4885CSNK1A1 71/4885IKZF2 3471/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | CRBN 194/4885CSNK1A1 48/4885IKZF2 1536/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.